ClinicalTrials.gg
Not yet recruitingNCT07613450Updated May 29, 2026

A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas

A Phase 3 interventional study of SYHA1813 and Investigator's Choice Treatment in High Grade Meningioma, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.

Read the detailed description

Approximately136 participants with recurrent or progressive high-grade meningioma who have received surgical resection and radiotherapy will be enrolled and randomized 1:1 to receive either SYHA1813 (experimental group) or investigators' choice (control group) treatment. The primary endpoint is progression-free survival (PFS) assessed by blinded Independent Review Committee (BIRC) using the Response Assessment in Neuro-Oncology Working Group (RANO criteria) for meningioma.

02

Conditions studied

  • High Grade Meningioma

Browse trials for

03

In context

Meningioma

255 studies on the registry are indexed under Meningioma; 85 are open to participants now.

This study's planned enrollment of 136 is above the median of 40 across 180 interventional studies indexed under Meningioma.

Browse Meningioma studies →

Lead sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Aged >= 18 years.
  • 2. confirmed WHO grade II/III meningioma (WHO CNS 5th) that is progressive or recurrent.
  • 3. Individuals must have received surgery and radiation therapy.
  • 4. There is at least one measurable intracranial tumor lesion in the baseline period (RANO-meningioma).
  • 5. ≥60.
  • 6. The expected survival time is >=3 months.
  • 7. The organ function level and related laboratory indicators must meet requirement.
  • 8. Agree to use reliable and effective methods of during the study treatment period and for at least 3 months after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  • 1. Individuals who are known to have severe allergic reaction to the study drug or any other ingredients/ in the formulation.
  • 2. Meets one of the following conditions: patients with brainstem involvement or extracranial ; patients with severe brain herniation or at risk of brain herniation.
  • 3. History of other malignant tumors within 3 years or concurrent active malignant tumors.
  • 4. The toxic reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade 1.
  • 5. Have used potent inhibitors or inducers of , CYP2C19 or CYP1A2 within the 14 days prior to randomization or are still requiring continued use of such agents.
  • 6. Individuals currently receiving warfarin or other oral anticoagulants (excluding those who use low-dose anticoagulants to maintain patency of central venous access or prevent deep vein thrombosis).
  • 7. Individuals who are unable to undergo enhanced MRI (such as those with pacemakers, metal dentures, claustrophobia, contrast agent allergies, etc.).
  • 8. Individuals with evidence or medical history of bleeding tendency within 2 months prior to randomization.
  • 9. Individuals with urine protein ≥ 2+, and 24-hour quantitative urine protein ≥ 1.0 g/24 h upon testing.
  • 10. History of acquired immunodeficiency syndrome or antibody positivity in the past; Active ; Active .
  • 11. Individuals with poorly healing wounds or ulcers, or fractures that require treatment or exhibit poor healing.
  • 12. Within 14 days prior to randomization, there were severe chronic or active infections (including tuberculosis infections) that required intravenous injection of antibacterial, antifungal or antiviral therapy.
  • 13. Individuals with cardiovascular and cerebrovascular diseases of significant clinical significance.
  • 14. Have undergone surgery of major vital organs within 28 days prior to randomization (excluding puncture ).
  • 15. Individuals with swallowing difficulties or known medication absorption disorders.
  • 16. Pregnant or lactating women.
  • 17. Any other conditions that may interfere with the participant's adherence to study procedures, compromise the participant's best interests in participating in the study, or affect study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Experimental group

    SYHA1813

    Drug: SYHA1813

  • Active comparator
    Control group

    Investigator's Choice Treatment

    Drug: Investigator's Choice Treatment

Interventions

  • SYHA1813 20mg QD

  • DrugInvestigator's Choice Treatment

    Investigator's Choice Treatment:bevacizumab, temozolomide or hydroxyurea

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by RANO Criteria and Evaluated by BIRC

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. PFS as Assessed by RANO Criteria and Evaluated by investigators

    Time frame: Up to approximately 4 years

  2. Overall Survival (OS)

    Time frame: Up to approximately 4 years

  3. Overall Survival Rate at 12 Months (OS-12)

    Time frame: Up to approximately 4 years

  4. Progression Free Survival Rate at 6 Months (PFS-6) as Assessed by RANO Criteria

    Time frame: Up to approximately 4 years

  5. Objective Response Rate (ORR) as Assessed by RANO Criteria

    Time frame: Up to approximately 4 years

  6. Disease Control Rate (DCR) as Assessed by RANO Criteria

    Time frame: Up to approximately 4 years

  7. Frequency and severity of TEAEs and SAEs

    Time frame: Up to approximately 4 years

  8. Cmax of SYHA1813

    Time frame: Cycles 1, 2, 3

  9. Tmax of SYHA1813

    Time frame: Cycles 1, 2, 3

  10. AUClast of SYHA1813

    Time frame: Cycles 1, 2, 3

  11. AUCinf of SYHA1813

    Time frame: Cycles 1, 2, 3

  12. t1/2 of SYHA1813

    Time frame: Cycles 1, 2, 3

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jul 2029, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 29, 2026
StartEst.
May 20, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Oct 15, 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07613450
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 20, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Oct 15, 2029 (estimated)
Last update
May 29, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHA1813

Start the discussion